Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Articles

A review article summarized the totality of evidence supporting the approval of the adalimumab biosimilar GP2017 (Hyrimoz; Sandoz) in the United States and Europe.

The Totality of Evidence Supporting the Approval of Adalimumab Biosimilar GP2017

Cameron Santoro is an associate editor for The Center for Biosimilars

Videos

Here are the top 5 biosimilar articles for the week of April 22, 2024. 

The Top 5 Biosimilar Articles for the Week of April 22

Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a total of €77.7 million, according to its annual earnings report.

Formycon Reports 83% Revenue Increase in 2023

Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.

AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Camlyn Masuda, PharmD, BCACP, CDCES, is an associate specialist of pharmacy practice at the Daniel K. Inouye College of Pharmacy at the University of Hawai’i at Hilo.

Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.

Common Patient Questions About Insulin Biosimilars Pertain to Classification